These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 37576392)
21. Multicenter cohort analysis of anoikis and EMT: implications for prognosis and therapy in lung adenocarcinoma. Yin L; Zhang Z; Yan Z; Yan Q Discov Oncol; 2024 Sep; 15(1):462. PubMed ID: 39298078 [TBL] [Abstract][Full Text] [Related]
22. DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma. Fan W; Xing Y; Yan S; Liu W; Ning J; Tian F; Wang X; Zhan Y; Luo L; Cao M; Huang J; Cai L Cancer Cell Int; 2024 Jun; 24(1):208. PubMed ID: 38872157 [TBL] [Abstract][Full Text] [Related]
23. High SERPINH1 expression predicts poor prognosis in lung adenocarcinoma. Zhang H; Yan X; Gu H; Xue Q; Liu X J Thorac Dis; 2022 Dec; 14(12):4785-4802. PubMed ID: 36647484 [TBL] [Abstract][Full Text] [Related]
24. SPP1 facilitates cell migration and invasion by targeting COL11A1 in lung adenocarcinoma. Yi X; Luo L; Zhu Y; Deng H; Liao H; Shen Y; Zheng Y Cancer Cell Int; 2022 Oct; 22(1):324. PubMed ID: 36266702 [TBL] [Abstract][Full Text] [Related]
25. Upregulation of POC1A in lung adenocarcinoma promotes tumour progression and predicts poor prognosis. Li ZH; Li JY; Wu ZT; Zhu YJ; Zhuo T; Nong JS; Qian J; Peng HJ; Dai L; Wang YY; Chen MW; Zeng XC J Cell Mol Med; 2024 Mar; 28(6):e18135. PubMed ID: 38429900 [TBL] [Abstract][Full Text] [Related]
26. High expression of DARS2 indicates poor prognosis in lung adenocarcinoma. Jiang Y; You J; Wu C; Kang Y; Chen F; Chen L; Wu W J Clin Lab Anal; 2022 Oct; 36(10):e24691. PubMed ID: 36085578 [TBL] [Abstract][Full Text] [Related]
27. Development and Validation of a Ferroptosis-Related Gene Signature for Overall Survival Prediction in Lung Adenocarcinoma. Tian Q; Zhou Y; Zhu L; Gao H; Yang J Front Cell Dev Biol; 2021; 9():684259. PubMed ID: 34307361 [No Abstract] [Full Text] [Related]
28. Integrated analysis and validation reveal ACAP1 as a novel prognostic biomarker associated with tumor immunity in lung adenocarcinoma. Wang N; Zhu L; Xu X; Yu C; Huang X Comput Struct Biotechnol J; 2022; 20():4390-4401. PubMed ID: 36051873 [TBL] [Abstract][Full Text] [Related]
29. Expression of gasdermin D in clear cell renal cell carcinoma and its effect on its biological function. Zhang J; Wang Y; Ma J; Aimudula A Front Oncol; 2023; 13():1163714. PubMed ID: 37483501 [TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma. Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y Front Immunol; 2022; 13():950001. PubMed ID: 36091041 [TBL] [Abstract][Full Text] [Related]
31. AVEN: a novel oncogenic biomarker with prognostic significance and implications of AVEN-associated immunophenotypes in lung adenocarcinoma. Fan D; Yang M; Lee HJ; Lee JH; Kim HS Front Mol Biosci; 2023; 10():1265359. PubMed ID: 37908231 [No Abstract] [Full Text] [Related]
32. The role of radiotherapy-related autophagy genes in the prognosis and immune infiltration in lung adenocarcinoma. Gao J; Lu F; Yan J; Wang R; Xia Y; Wang L; Li L; Chang L; Li W Front Immunol; 2022; 13():992626. PubMed ID: 36311724 [TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis to identify GNG7 as a prognostic biomarker in lung adenocarcinoma correlating with immune infiltrates. Wei Q; Miao T; Zhang P; Jiang B; Yan H Front Genet; 2022; 13():984575. PubMed ID: 36159963 [No Abstract] [Full Text] [Related]
34. High Expression of Chen Y; Zhou M; Gu X; Wang L; Wang C Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850 [TBL] [Abstract][Full Text] [Related]
35. LncRNA-AC068228.1 Is a Novel Prognostic Biomarker That Promotes Malignant Phenotypes in Lung Adenocarcinoma. Jiang X; Chen M; Du J; Bi H; Guo X; Yang C; He X; Jin Z Front Oncol; 2022; 12():856655. PubMed ID: 35280807 [TBL] [Abstract][Full Text] [Related]
36. Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma. Yang J; Luo G; Li C; Zhao Z; Ju S; Li Q; Chen Z; Ding C; Tong X; Zhao J BMC Cancer; 2022 May; 22(1):589. PubMed ID: 35637432 [TBL] [Abstract][Full Text] [Related]
37. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma. Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451 [TBL] [Abstract][Full Text] [Related]
38. Analysis of prognostic genes in the tumor microenvironment of lung adenocarcinoma. Xu ZY; Zhao M; Chen W; Li K; Qin F; Xiang WW; Sun Y; Wei J; Yuan LQ; Li SK; Lin SH PeerJ; 2020; 8():e9530. PubMed ID: 32775050 [TBL] [Abstract][Full Text] [Related]
39. Identifying the EMT-related signature to stratify prognosis and evaluate the tumor microenvironment in lung adenocarcinoma. Li F; Song QZ; Zhang YF; Wang XR; Cao LM; Li N; Zhao LX; Zhang SX; Zhuang XF Front Genet; 2022; 13():1008416. PubMed ID: 36186418 [No Abstract] [Full Text] [Related]
40. FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor. Yu L; Qiao R; Xu J; Han B; Zhong R Life Sci; 2021 Mar; 268():119022. PubMed ID: 33434533 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]